Naslov
Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation

Autori
Perić, Zinaida ; Cahu, Xavier ; Chevallier, Patrice ; Brissot, Eolia ; Malard, Florent ; Guillaume, Thierry ; Delaunay, Jacques ; Ayari, Sameh ; Dubruille, Viviane ; Le Gouill, Steven ; Mahé, Beatrice ; Gastinne, Thomas ; Blin, Nicolas ; Saulquin, Beatrice ; Harousseau, Jean-Luc ; Moreau, Philippe, Coste-Burel, Marianne ; Imbert- Marcille, Berthe-Marie ; Mohty, Mohamad

Izvornik
Bone marrow transplantation (Basingstoke) (0268-3369) 47 (2012), 2; 251-257

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
EBV; RIC; cord blood; stem cell transplantation

Sažetak
This single centre study assessed the incidence, kinetics and predictive factors of EBV reactivation and EBV-related lymphoproliferative diseases (LPD) in 33 consecutive patients who received a reduced intensity conditioning (RIC) before umbilical cord blood transplantation (UCBT). During the first 6 months after UCBT, weekly all patients were DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. The cumulative incidences of EBV reactivation (defined as an EBV load >1000 EBV copies per 10(5) cells measured at least once during follow-up) at 6 months and 2 years after UCBT were 9 (95% confidence interval (CI), 2-22%) and 17% (95% CI, 6-33%), respectively. In 28 patients (85%), the EBV load remained negative at all times, and none of these patients experienced any sign of LPD. Five patients (15%) experienced at least one EBV reactivation episode. EBV reactivation was observed at a median of 132 days (range, 85-438) after UCBT. Two patients developed EBV-related LPD (cumulative incidence, 6% at 3 years). With a median follow-up of 468 days (range, 92-1277) post UCBT, the OS was 62% at 3 years. Five patients died of disease progression and seven patients died of transplant-related complications, including one case of EBV-related LPD. Univariate analysis did not identify any significant risk factor associated with EBV reactivation. We conclude that patients undergoing RIC UCBT are at risk for EBV reactivation, with the need for close EBV monitoring and the use of preemptive rituximab treatment as some cases may progress to life- threatening LPD.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA